Promising combo targets rare leukemia

NCT ID NCT00412594

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a two-step treatment for hairy cell leukemia, a rare blood cancer. First, patients receive chemotherapy (cladribine) to kill cancer cells, then an immunotherapy drug (rituximab) to help the immune system attack any remaining cells. The goal is to see if adding rituximab leads to more complete remissions and longer disease control. The trial is for adults with newly diagnosed or relapsed disease who have had no more than one prior treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HAIRY CELL LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hairy cell leukemia refractory hairy cell leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HAIRY CELL LEUKEMIA RECURRENT HAIRY CELL LEUKEMIA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

M D Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact